Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer

Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer

Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castrat...

Full description

Bibliographic Details
Main Authors: L. K. Ovchinnikova, A. D. Belko
Format: Article
Language:Russian
Published: Remedium Group LLC 2019-06-01
Series:Медицинский совет
Subjects:
hormone-dependent breast cancer
drug ovarian suppression
buserelin-depo
Online Access:https://www.med-sovet.pro/jour/article/view/3057
id doaj-51b60b60735c4f96a8bf532bbf41c185
record_format Article
spelling doaj-51b60b60735c4f96a8bf532bbf41c1852021-07-28T13:29:41ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-06-01010879110.21518/2079-701X-2019-10-87-912971Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancerL. K. Ovchinnikova0A. D. Belko1State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.https://www.med-sovet.pro/jour/article/view/3057hormone-dependent breast cancerdrug ovarian suppressionbuserelin-depo
collection DOAJ
language Russian
format Article
sources DOAJ
author L. K. Ovchinnikova
A. D. Belko
spellingShingle L. K. Ovchinnikova
A. D. Belko
Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
Медицинский совет
hormone-dependent breast cancer
drug ovarian suppression
buserelin-depo
author_facet L. K. Ovchinnikova
A. D. Belko
author_sort L. K. Ovchinnikova
title Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
title_short Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
title_full Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
title_fullStr Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
title_full_unstemmed Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
title_sort efficacy and safety of adjuvant ovarian suppression with buserelin-depo in premenopausal women with hormone-positive breast cancer
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2019-06-01
description Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.
topic hormone-dependent breast cancer
drug ovarian suppression
buserelin-depo
url https://www.med-sovet.pro/jour/article/view/3057
work_keys_str_mv AT lkovchinnikova efficacyandsafetyofadjuvantovariansuppressionwithbuserelindepoinpremenopausalwomenwithhormonepositivebreastcancer
AT adbelko efficacyandsafetyofadjuvantovariansuppressionwithbuserelindepoinpremenopausalwomenwithhormonepositivebreastcancer
_version_ 1721273818238943232

Similar Items